Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cytokinetics: Update on Extensive Clinical Trials Being Conducted (CYTK, Buy, $9.45)

Investment Overview and Thesis Cytokinetics has an extremely valuable asset in omecamtiv mecarbil, which it is developing in collaboration with Amgen; it is currently being studied in the huge, 8000+ patient, GALACTIC-HF phase 3 trial. I believe that this drug which is being studied in congestive heart failure is potentially one of the most important […]

«Older Posts
«Older Posts
Search Graphic